micafungin + caspofungin

Phase 3Completed
3 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Oral

Conditions

Candidiasis, Oral

Trial Timeline

Jun 1, 2004 → Dec 1, 2004

About micafungin + caspofungin

micafungin + caspofungin is a phase 3 stage product being developed by Astellas Pharma for Candidiasis, Oral. The current trial status is completed. This product is registered under clinical trial identifier NCT00665639. Target conditions include Candidiasis, Oral.

What happened to similar drugs?

5 of 20 similar drugs in Candidiasis, Oral were approved

Approved (5) Terminated (4) Active (12)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00105144Phase 3Completed
NCT00665639Phase 3Completed

Competing Products

20 competing products in Candidiasis, Oral

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
29
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Fluconazole + MicafunginAstellas PharmaApproved
35
Micafungin + CaspofunginAstellas PharmaPhase 3
40
Micafungin + FluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPhase 2
35
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
32
FK463Astellas PharmaPhase 2
35
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
40
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
36
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
36
L-743,872MerckPre-clinical
26
CaspofunginMerckPhase 2
35
L-743,872MerckPhase 2
27
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
27
Caspofungin acetate + PlaceboMerckPhase 2
27
Caspofungin + Normal SalineMerckApproved
43
caspofungin acetateMerckPhase 3
40